Posts

Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics

/by

Knowledge about the therapeutic potential of medical cannabis has greatly improved over the past decade, with an ever-increasing range of developments in human clinical applications. A growing body of scientific evidence supports the use of medical cannabis products for some therapeutic indications, whilst for others, the evidence base remains disputed. For this narrative review, we incorporate areas where the current evidence base is substantial, such as intractable childhood epilepsy and multiple sclerosis, as well as areas where the evidence is still controversial, such as PTSD and anxiety.

Read more

Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma

/by

Cannabidiol (CBD) has anti-tumorigenic activity. However, the anti-cancer effect of CBD on head and neck squamous cell carcinoma (HNSCC) remains unclear. The cytotoxicity of CBD on HNSCC was analyzed using cell survival and colony-forming assays in vitro. RNA-seq was used for determining the mechanism underlying CBD-induced cell death.

Read more

Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid Receptor-1 and Transient Receptor Potential Vanilloid-1

/by

We have recently shown that lipid mediators of the emerging endocannabinoid system (ECS) are key players of growth control of the human pilosebaceous unit. In this study, we asked whether the prototypic endocannabinoid anandamide (N-arachidonoylethanolamine, AEA) has a role in growth and survival of epidermal keratinocytes (KCs).

Read more

Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis

/by

Cannabinoids from cannabis (Cannabis sativa) are anti-inflammatory and have inhibitory effects on the proliferation of a number of tumorigenic cell lines, some of which are mediated via cannabinoid receptors. Cannabinoid (CB) receptors are present in human skin and anandamide, an endogenous CB receptor ligand, inhibits epidermal keratinocyte differentiation. Psoriasis is an inflammatory disease also characterised in part by epidermal keratinocyte hyper-proliferation.

Read more

Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

/by

The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway.

Read more

Self‐initiated use of topical cannabidiol oil for epidermolysis bullosa

/by

Epidermolysis bullosa is a rare blistering skin disorder that is challenging to manage because skin fragility and repeated wound healing cause itching, pain, limited mobility, and recurrent infections. Cannabidiol, an active cannabinoid found in cannabis, is postulated to have antiinflammatory and analgesic effects.

Read more

Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy

/by

To evaluate the safety, efficacy, and tolerability of highly purified cannabidiol (CBD) for the treatment of seizures in children and adults with treatment-resistant epilepsy (TRE) in an open-label, expanded access program (EAP).

Read more

Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review

/by

Authors Alessia Furgiuele, Marco Cosentino, Marco Ferrari & Franca Marino Published in Journal of Neuroimmune Pharmacology January 2021 Abstract Multiple sclerosis (MS) is the most common chronic autoimmune disease of…

Read more

Use of Cannabis for Self-Management of Chronic Pelvic Pain

/by

SCC member Kenzi Riboulet-Zemouli identifies a coherent nomenclature for cannabis products (whether derived from Cannabis sativa L. or not). The paper was published in Drug Science, Policy and Law in December of 2020.

Read more

Safety Considerations in Cannabinoid-Based Medicine

/by

Authors Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Anton Uribayev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Mahmud Abo-Amna, Luiza Akria, Dmitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Or Hazan,…

Read more

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

/by

Authors: Serena Silvestro, Giovanni Schepici, Placido Bramanti, and Emanuela Mazzon Published in Molecules November 2020 Abstract The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-Cannabidiol…

Read more

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

/by

Authors: Ayat Zagzoog, Kawthar A. Mohamed, Hye Ji J. Kim, Eunhyun D. Kim, Connor S. Frank, Tallan Black, Pramodkumar D. Jadhav, Larry A. Holbrook & Robert B. Laprairie Published in…

Read more